b
cell
one
key
player
pathogenesi
multipl
sclerosi
ms
peripher
b
cell
distribut
similar
healthi
person
ms
patient
healthi
control
b
cell
rare
present
cerebrospin
fluid
csf
ms
patient
clonal
expand
b
cell
popul
detect
consist
memori
b
cell
centroblast
antibodysecret
plasma
blast
plasma
cell
respons
intrathec
immunoglobulin
g
product
oligoclon
band
format
ms
patient
unfortun
target
autoreact
b
cell
antibodi
remain
larg
unknown
variou
candid
antigen
identifi
often
involv
diseas
process
still
unclear
studi
character
target
antigen
examin
autoantibodi
analyz
sera
csf
ms
patient
altern
approach
focus
clonal
expand
b
cell
way
b
cell
direct
myelin
astroglia
axon
denot
ms
patient
b
cell
immort
base
antibodyproduc
potenti
epsteinbarr
viru
ebv
transform
b
cell
use
expand
b
cell
ms
patient
product
antibodi
ultim
analys
target
identif
csf
serum
patient
ms
indic
intrathec
immunoglobulin
ig
product
presenc
b
cell
plasma
cell
complement
myelinspecif
antibodi
chronic
ms
lesion
restrict
ig
gene
usag
pattern
variabl
region
heavi
chain
v
h
locu
csf
b
cell
suggest
antigendriven
humor
immun
respons
cn
ms
addit
b
cell
folliclelik
structur
character
brain
mening
ms
patient
recent
posit
result
achiev
use
b
cell
deplet
antibodi
rituximab
clinic
trial
find
contribut
compel
evid
humor
immun
respons
implic
pathogenesi
ms
b
cell
exert
differ
function
ms
pathogenesi
name
complement
fixat
cellmedi
cytotox
antigen
present
cell
costimul
cytokin
neurotroph
factor
product
research
focus
autoantibodi
product
numer
approach
current
use
investig
b
cell
reactiv
differ
success
rate
despit
lot
effort
yet
known
target
autoreact
b
cell
antibodi
sinc
ms
character
heterogen
diseas
cours
genet
background
novel
marker
diagnosi
new
patient
multiplex
treatment
strategi
need
better
control
diseas
studi
humor
immun
respons
thu
remain
hot
topic
ms
research
identif
target
antigen
character
b
cell
repertoir
two
main
goal
matur
b
cell
character
express
gener
b
cell
marker
absenc
surfac
releas
peripher
blood
develop
bone
marrow
secondari
lymphoid
organ
recognit
antigen
lymphoid
tissu
trigger
b
cell
activ
accompani
upregul
surfac
express
activ
b
cell
prolifer
plasma
blast
produc
lowaffin
antibodi
day
differenti
differ
effector
b
cell
subtyp
germin
center
gc
via
centrocyt
centroblast
stage
accompani
upregul
surfac
express
case
memori
b
cell
plasma
blast
plasma
cell
develop
extens
mutat
matur
memori
b
cell
express
memori
surfac
marker
abl
reactiv
differenti
plasma
cell
fast
upon
new
challeng
antigen
plasma
blast
shortliv
antibodysecret
cell
express
also
plasma
cell
marker
plasma
cell
lost
prolifer
capac
mostli
longliv
antibodyproduc
cell
longer
display
express
healthi
individu
b
cell
popul
peripher
blood
belong
b
cell
popul
although
circul
memori
b
cell
denot
antibodysecret
effector
cell
move
target
tissu
elimin
target
cell
consequ
found
blood
b
cell
rare
found
csf
healthi
person
patient
noninflammatori
neurolog
diseas
nind
healthi
individu
b
cell
peripher
blood
ms
patient
predominantli
display
phenotyp
csf
ms
patient
patient
inflammatori
neurolog
disord
oind
contain
averag
b
cell
opposit
situat
healthi
person
variabl
csf
b
cell
number
seen
patient
major
matur
memori
b
cell
high
centroblast
normal
occur
gc
lymphat
tissu
demonstr
csf
either
result
circul
memori
b
cell
recruit
cn
intrathec
differenti
b
cell
process
promot
ectop
gc
identifi
brain
mening
ms
patient
suggest
antibodysecret
cell
gener
within
cn
plasma
blast
also
describ
import
csf
b
cell
popul
number
plasma
blast
significantli
increas
ms
patient
patient
clinic
isol
syndrom
ci
compar
oind
patient
furthermor
number
matur
memori
b
cell
plasma
blast
csf
ms
patient
correl
intrathec
igg
igm
product
higher
diseas
activ
lesion
magnet
reson
imag
mri
total
csf
leukocyt
number
intrathec
product
matrix
metalloproteinas
home
chemokin
find
indic
csf
b
cell
play
role
acut
inflamm
preval
antibodysecret
cell
csf
plasma
blast
held
respons
intrathec
igg
product
consequ
mention
main
effector
b
cell
popul
acut
inflamm
ms
normal
plasma
blast
shortliv
antibodysecret
cell
rapidli
differenti
fulli
matur
plasma
cell
ms
howev
plasma
blast
number
remain
virtual
constant
time
might
demonstr
antigendriven
chronic
b
cell
stimul
cn
disagr
exist
concern
contribut
plasma
cell
b
cell
repertoir
csf
compart
studi
point
low
number
plasma
cell
anoth
studi
demonstr
high
number
plasma
cell
csf
ms
patient
case
limit
number
ms
patient
use
anyhow
distribut
plasma
blast
matur
plasma
cell
csf
remain
vagu
although
cell
recent
shown
deriv
progenitor
pool
thu
repres
converg
respons
absenc
plasma
cell
csf
ms
patient
could
explain
fact
plasma
cell
migrat
brain
mening
parenchyma
hard
detect
csf
moreov
surfac
marker
express
profil
entir
clarifi
plasma
cell
plasma
blast
previous
even
shown
express
surfac
plasma
blast
consequ
surfac
marker
allow
differenti
plasma
cell
plasma
blast
thu
phenotyp
differ
two
cell
type
still
determin
detail
tabl
give
overview
differ
b
cell
subset
surfac
marker
express
profil
distribut
among
peripher
blood
csf
multipl
candid
antigen
alreadi
identifi
differ
studi
evid
role
diseas
process
still
lack
involv
specif
ms
myelin
oligodendrocyt
glycoprotein
mog
myelin
basic
protein
mbp
proteolipid
protein
plp
myelinassoci
glycoprotein
mag
phosphatidylcholin
galactocerebrosid
galc
myelin
protein
mention
possibl
autoantigen
ms
humor
respons
axon
neuron
antigen
cytoskelet
neurofila
protein
gangliosid
correl
diseas
progress
virus
also
shown
particip
abnorm
humor
immun
respons
ms
includ
epsteinbarr
viru
ebv
human
herp
viru
type
cytomegaloviru
cmv
measl
chlamydia
pneumonia
addit
protect
antibodi
caus
remyelin
myelin
repair
found
antibodi
direct
oligodendrocyt
surfac
antigen
heath
shock
protein
studi
investig
specif
humor
immun
respons
focus
autoantibodi
directli
analyz
reactiv
antibodi
serum
csf
ms
patient
versu
healthi
control
neurolog
control
patient
substanti
amount
candid
autoantigen
mention
denot
way
serum
may
ideal
specimen
studi
autoantibodi
ms
oligoclon
immunoglobulin
present
cn
consequ
antibodi
unrel
diseas
may
hamper
identif
diseasespecif
antibodi
csf
use
surrog
brain
microenviron
would
therefor
suitabl
studi
antibodi
respons
ms
although
csf
may
also
compris
antibodi
origin
serum
howev
relev
autoreact
antibodi
may
bind
target
fc
receptor
cn
tissu
therebi
render
undetect
csf
altern
approach
studi
msrelat
antigen
would
investig
reactiv
clonal
expand
b
cell
csf
despit
low
csf
b
cell
number
sever
target
antigen
alreadi
identifi
describ
group
link
perform
differ
studi
b
cell
reactiv
use
immunospot
assay
nitrocellulos
microtit
plate
coat
antigen
interest
bind
peripher
blood
mononuclear
cell
pbmc
csf
cell
antigen
detect
studi
csf
cell
pbmc
ms
patient
mbpreactiv
csf
b
cell
found
ms
patient
none
present
peripher
blood
magreact
b
cell
indic
csf
pbmc
ms
patient
patient
respect
furthermor
antimog
igg
secret
cell
demonstr
peripher
blood
ms
patient
csf
ms
patient
studi
made
use
recombin
antibodi
produc
patient
csf
b
cell
cell
csf
singlecel
sort
pcr
plate
variabl
region
heavi
light
ig
chain
v
h
v
l
amplifi
clone
plasmid
vector
express
bacteri
express
system
correspond
recombin
antibodi
ultim
use
reactiv
screen
immunoprecipit
western
blot
elisa
immunohistochemistri
lambrachtwashington
cowork
discov
reactiv
recombinantli
produc
antibodi
toward
mbp
nucleotid
cnpase
glial
fibrillari
acid
protein
gfap
hand
von
et
al
produc
recombin
ms
antibodi
follow
procedur
case
display
myelin
reactiv
direct
astroglia
apart
myelin
bind
ms
brain
tissu
target
could
identifi
use
sever
techniqu
costain
known
myelin
antigen
brain
tissu
immunohistochemistri
western
blot
human
myelin
elisa
use
recombin
nativ
mog
mbp
yet
anoth
studi
zhang
et
al
recombin
antibodi
ms
csf
produc
demonstr
reactiv
axon
patholog
chang
ms
brain
tissu
target
later
identifi
triosephosph
isomeras
tpi
dehydrogenas
gapdh
recent
adapt
b
cell
immort
techniqu
studi
b
cell
respons
ms
base
csf
peripher
blood
b
cell
technolog
first
use
consist
b
cell
infect
ebv
produc
marmoset
lymphocyt
cell
line
obtain
continu
divid
b
cell
line
unsuccess
due
low
effici
immort
slow
growth
rate
b
cell
sometim
low
antibodi
product
lot
adjust
made
technolog
sinc
fusion
ebv
immort
cell
mous
myeloma
humanmous
heteromyeloma
addit
cell
deriv
growth
factor
cytokin
without
success
traggiai
et
al
publish
improv
b
cell
immort
method
base
combin
ebv
polyclon
b
cell
activ
cpg
oligonucleotid
produc
antibodi
capac
neutral
sar
coronaviru
base
success
develop
optim
b
cell
immort
procedur
isol
immort
b
cell
line
csf
peripher
blood
ms
patient
low
number
total
csf
cell
pbmc
cell
per
well
infect
ebv
presenc
cpg
oligonucleotid
interleukin
give
optim
b
cell
stimul
unmethyl
dna
sequenc
capabl
stimul
b
cell
tolllik
receptor
ligat
cell
suppress
agent
cyclosporin
csa
irradi
allogen
pbmc
feeder
cell
ad
cultur
way
b
cell
transform
continu
divid
b
cell
line
verifi
screen
cultur
supernat
presenc
human
igg
use
dot
blot
techniqu
iggposit
immort
b
cell
cultur
repres
enrich
b
cell
popul
vivo
maintain
antibodi
product
clonal
examin
use
b
cell
spectratyp
procedur
igh
gene
clonal
assay
invivoscrib
specif
antibodi
produc
immort
b
cell
line
determin
use
varieti
techniqu
elisa
immunohistochemistri
immunoprecipit
western
blot
cdna
phage
display
b
cell
emerg
key
player
lot
autoimmun
diseas
ms
b
cell
repertoir
csf
ms
patient
alreadi
intens
studi
howev
rel
contribut
differ
b
cell
subset
intrathec
igg
product
ocb
format
still
defin
addit
site
csf
b
cell
activ
peripheri
cn
phenotyp
differ
plasma
cell
plasma
blast
determin
detail
specif
autoreact
b
cell
antibodi
remain
unclear
despit
numer
studi
use
differ
techniqu
studi
focus
antibodi
reactiv
examin
serum
csf
antibodi
ms
patient
altern
approach
analyz
reactiv
expand
b
cell
cn
adapt
b
cell
immort
method
analysi
b
cell
respons
peripher
blood
csf
ms
patient
next
step
target
antigen
isol
immort
b
cell
identifi
use
spectrum
techniqu
b
cell
immort
may
also
promis
altern
studi
humor
respons
gener
fig
b
cell
immort
procedur
total
csf
cell
pbmc
infect
ebv
presenc
b
cell
stimul
factor
cpg
oligonucleotid
cell
suppress
factor
csa
irradi
allogen
pbmc
feeder
cell
sourc
ebv
cultur
supernat
cell
line
use
immort
phase
cultur
screen
presenc
iggposit
b
cell
dot
blot
human
igg
posit
control
purifi
human
igg
use
serial
dilut
co
posit
cultur
maintain
product
antibodi
later
screen
character
identif
target
antigen
b
cell
research
ms
focus
autoantibodi
product
target
autoreact
b
cell
antibodi
remain
unknown
variou
candid
antigen
identifi
relev
diseas
process
discuss
b
cell
popul
csf
ms
consist
clonal
expand
memori
b
cell
centroblast
antibodysecret
plasma
blast
plasma
cell
gener
sustain
within
central
nervou
system
cn
disagr
exist
concern
contribut
plasma
cell
b
cell
repertoir
csf
phenotyp
differ
plasma
blast
plasma
cell
determin
detail
clarifi
distribut
reactiv
screen
clonal
expand
b
cell
csf
ms
patient
appropri
investig
role
diseas
process
b
cell
immort
promis
approach
studi
humor
respons
use
ebv
transform
b
cell
antibodyproduc
b
cell
line
specif
produc
antibodi
determin
use
spectrum
techniqu
immunohistochemistri
immunoprecipit
cdna
phage
display
